CGTN
10.2.2021 19:16:04 CET | Business Wire | Press release
A New Year is a new beginning. With this year's Spring Festival, or the Chinese Lunar New Year, just around the corner, China is also well prepared for the beginning of the 14th Five-Year Plan (FYP) period (2021-2025) and the centenary of the Communist Party of China (CPC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005816/en/
Ahead of the Spring Festival, Chinese President Xi Jinping extended Spring Festival greetings to all Chinese Wednesday at a reception in Beijing and called for a good start in boosting the country's development during the 14th FYP period so as to celebrate the Party's centenary with outstanding achievements.
Ready for a new journey in the 14th FYP period
Facts have once again proven that the system of socialism with Chinese characteristics has incomparable vitality and creativity, Xi said.
As long as the entire Party and the Chinese people of all ethnic groups rally closely around the CPC Central Committee, there is no difficulty that cannot be overcome, he said.
The year 2021 is crucial to China as the nation is set to achieve its first centenary goal within the set time frame – to complete the building of a moderately prosperous society in all respects – and begin the work towards the second goal, to fully build a modern socialist country.
Stressing the goal of promoting high-quality development, President Xi highlighted the importance of the country's new stage of development, the implementation of this new vision of development, and the construction of a new pattern of development in 2021.
To meet the people's ever-growing needs for a better life, efforts are needed in deepening supply-side structural reform while taking reform and innovation as the fundamental driving force, the Chinese president said.
Consolidating and expanding achievements in epidemic containment and economic and social development are necessary, he added.
Great achievements in 2020 as solid foundation
President Xi also looked back on the past year which he described as "extraordinary" in his New Year speech.
Xi hailed what has achieved in COVID-19 prevention, poverty alleviation, flood prevention, rescue and relief work, and reform and opening-up, and highlighted the country's progress in technology, economy and the Belt and Road construction.
China is one of the most resilient economies amid the ravaging pandemic and global economic slump. The country was among the first to have put the virus under control, to have resumed work and production and to have realized economic stability and recovery, which not only made it the first major economy in the world to register positive growth in 2020 but also brought confidence and hope to others in the world.
On November 23, as southwest China's Guizhou Province cleared all the names on its poverty list, China announced the eradication of absolute poverty and regional poverty.
At a symposium on securing a decisive victory in poverty alleviation in March, President Xi said lifting all rural residents living below the poverty line out of poverty by 2020 is a solemn promise made by the CPC Central Committee and it must be fulfilled on time.
Original article: here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005816/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
